Time To Grow: SK Bioscience Eyes US Vaccine, CGT Acquisitions This Year

CEO Doesn’t Believe CGT Market Faces Overcapacity

 
• By Jung Won Shin
  
Jae-Yong Ahn, CEO of SK Bioscience
SK Bioscience's Aggressive Investment Could Delay Its Turnaround For Few Years • Source: SK Bioscience
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia